Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
Net sales	$ 5,531,250	$ 5,353,166	$ 17,085,287	$ 15,971,424
Cost of sales	3,113,742	3,512,905	9,940,345	9,988,172
Asset impairment charge		407,141		407,141
Total cost of sales	3,113,742	3,920,046	9,940,345	10,395,313
Gross profit	2,417,508	1,433,120	7,144,942	5,576,111
Operating expenses:
Research and development	853,840	1,012,546	2,598,063	3,094,939
Selling, general and administrative	3,041,511	3,297,653	9,808,348	9,840,235
Total operating expenses	3,895,351	4,310,199	12,406,411	12,935,174
Operating loss	(1,477,843)	(2,877,079)	(5,261,469)	(7,359,063)
Interest Expense	226,341	86,927	566,895	229,482
Other income	(16,961)	(3,884)	(17,869)	(407,371)
Net loss	(1,687,223)	(2,960,122)	(5,810,495)	(7,181,174)
Preferred stock dividend accretion	325,367	303,553	959,409	895,087
Net loss applicable to common stockholders	$ (2,012,590)	$ (3,263,675)	$ (6,769,904)	$ (8,076,261)
Per share basic and diluted loss applicable to common stockholders	$ (0.10)	$ (0.19)	$ (0.35)	$ (0.55)
Weighted average number of common shares outstanding:
Basic and diluted	19,283,787	17,471,529	19,251,789	14,762,899